A Hong Kong study released in “The Lancet Public Health” and cited by “Bloomberg” concluded that BionTech’s vaccine produces more antibodies than Sinovac’s vaccine.
The study, which looks at different types of vaccine, found that antibody levels among Hong Kong healthcare professionals fully vaccinated with BioNTech’s mRNA vaccine are about 10 times higher than those seen in Sinovac Biotech’s inactivated vaccine recipients.
+ Pfizer’s vaccine effectiveness decreases in 6 months, Israel points out
Although disease-fighting antibodies are not responsible for the whole picture when it comes to measuring the ability to produce immunity and the effectiveness of Covid vaccines, “the difference in the concentrations of neutralizing antibodies identified in our study can be translated substantial differences in vaccine efficacy,” the scientists revealed.
The discovery thus adds to a body of evidence that indicates the superiority of mRNA vaccines in creating immunity against Sars-CoV-2 and its variants, compared to vaccines developed by more traditional methods, such as virus inactivation .
Countries from Israel to the US have relied primarily on vaccines using the mRNA technique from Pfizer, BioNTech, as well as Moderna have seen a marked reduction in infections. Countries that have used vaccines such as China’s Sinovac and Sinopharm have not had as much impact on the number of cases, although the use of both types has significantly avoided Covid and more serious fatalities.
The lower effectiveness of inactivated vaccines has led countries from Thailand to the United Arab Emirates to offer people already fully vaccinated another booster dose, as the more infectious delta variant fuels the resurgence of infections. The United States considered doing the same with Pfizer, but on Tuesday, July 13, decided that anyone who has already received two doses of covid-19 vaccine does not need to take a third dose.
+ Learn about the effectiveness of each vaccine against Covid-19